Predictive Technology Group and Atrin Pharmaceuticals are collaborating to develop molecular diagnostic tools to improve selection of cancer patients who would most benefit from treatment with DNA Damage and Response inhibitors, including Atrin’s and other small molecule ATR inhibitors.
The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.
